| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenues | 507,380 | - |
| Cost of goods sold | 51,555 | - |
| Selling expenses | 145,398 | - |
| Marketing expenses | 60,068 | - |
| General and administrative expenses | 86,833 | - |
| Acquisition-related expenses | 70,874 | - |
| ONAPGO | 1,613 | - |
| SPN820 | 8,073 | - |
| SPN817 | 11,889 | - |
| Qelbree | 9,805 | - |
| ZURZUVAE | 1,385 | - |
| Early Stage Program And Other | 11,865 | - |
| Total external development program expenses | 44,630 | - |
| Internal employee-related expenses | 33,778 | - |
| Total research and development expenses | 78,408 | - |
| Other segment items | 48,689 | - |
| Net earnings (loss) | -34,445 | 10,672 |
| Depreciation and amortization | 66,547 | 41,741 |
| Amortization of premium/discount on marketable securities | 2,027 | 1,106 |
| Change in fair value of contingent consideration | 7,660 | 7,660 |
| Realized gains from sales of marketable securities | 0 | - |
| Share-based compensation expense | 23,400 | 15,575 |
| Deferred income tax benefit | -13,797 | -11,152 |
| Inventory valuation write-down | 1,228 | 1,467 |
| Payment of contingent consideration | -4,900 | -4,900 |
| Other noncash adjustments, net | -7,606 | -3,779 |
| Accounts receivable | 5,885 | -1,246 |
| Inventories | 3,322 | -9,618 |
| Prepaid expenses and other assets | 6,274 | -4,870 |
| Accrued product returns and rebates | 15,754 | 12,211 |
| Accounts payable and other liabilities | -24,075 | -2,547 |
| Net cash provided by operating activities | 27,470 | 89,134 |
| Purchases of marketable securities | 385,741 | 259,113 |
| Maturities of marketable securities | 735,161 | 266,605 |
| Acquisition of sage, net of cash acquired | 293,093 | - |
| Purchases of property and equipment | 911 | 782 |
| Net cash provided by (used in) investing activities | 55,416 | 6,710 |
| Proceeds from issuance of common stock | 29,059 | 5,318 |
| Employee taxes paid related to net share settlement of equity awards | 4,198 | 3,387 |
| Payment of contingent consideration | 24,257 | 22,395 |
| Net cash provided by financing activities | 604 | -20,464 |
| Net change in cash, cash equivalents, and restricted cash | 83,490 | 75,380 |
| Cash and cash equivalents at beginning of period | 69,331 | - |
| Cash and cash equivalents at end of period | 152,821 | - |
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)